In published trials, 60–75% of chronic wounds treated with cell or exosome therapy achieved closure or substantial reduction (>90% area healing) within 16 weeks. Outcomes are better for small (≤10 cm²), acute-to-subacute wounds (6 months–1 year old) than for large, longstanding wounds. Patients with uncontrolled diabetes or severe vascular insufficiency show lower healing rates.
Chronic wound cell and exosome therapy has been subject to 59 completed trials, with 7 currently enrolling participants. Trials span diabetic foot ulcers (majority), pressure wounds, and mixed aetiology chronic wounds. Closure rates (percentage of wounds achieving full epithelial coverage) in treated cohorts typically range from 55–85% over 8–16 weeks, compared to reported historical control rates of 20–40% for advanced wounds. Exosome-based studies specifically show wound-area reduction averaging 45–70% at 12 weeks. Trial heterogeneity in wound selection, cell dose, and delivery (topical, intradermal injection, or fibrin-scaffold embedding) limits meta-analysis.
Съм ли кандидат? → · Chronic Wounds & Ulcers: full overview → · Цена Хронични рани и язви → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка